FDA 483 OBSERVATION · #328 OF 1,000 MOST-CITED
Thorough investigations
FDA cited this observation 64 times across 62 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
How FDA worded it — real examples
Failure to perform a thorough investigation and make a record of the conclusions and follow-up of an unexplained discrepancy.
Failure to perform a thorough investigation and make a record of the conclusions and follow-up of an unexplained discrepancy.
Failure to perform a thorough investigation and make a record of the conclusions and follow-up of an unexplained discrepancy.
Failure to perform a thorough investigation and make a record of the conclusions and follow-up of an unexplained discrepancy.
Failure to perform a thorough investigation and make a record of the conclusions and follow-up of an unexplained discrepancy.
Failure to perform a thorough investigation and make a record of the conclusions and follow-up of an unexplained discrepancy.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.